CAR T Cells Targeting CD19
Showing 1 - 25 of >10,000
SLE (Systemic Lupus) Trial in Bangkok (CAR T-cell therapy)
Not yet recruiting
- SLE (Systemic Lupus)
- CAR T-cell therapy
-
Bangkok, Please Select, ThailandKing Chulalongkorn Memorial Hospital
Nov 23, 2023
Chronic Lymphocytic Leukemia (CLL), Relapsed, Refractory Trial in New York (EGFRt/19-28z/4-1BBL CAR T cells)
Active, not recruiting
- Chronic Lymphocytic Leukemia (CLL)
- +2 more
- EGFRt/19-28z/4-1BBL CAR T cells
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Apr 1, 2022
SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)
Recruiting
- SLE (Systemic Lupus)
- +4 more
- CD19 targeted CAR-T cells
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Sep 25, 2023
Systemic Lupus Erythematosus (SLE) Trial (BRL-301)
Not yet recruiting
- Systemic Lupus Erythematosus (SLE)
- BRL-301
- (no location specified)
Aug 13, 2023
Lymphoma Trial in Seattle (biological, other, procedure)
Not yet recruiting
- Lymphoma
- Immune Globulin Infusion (Human), 10% Solution
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 21, 2023
Glioblastoma Multiforme of Brain Trial in Duarte (CHM-1101 CAR-T cells)
Not yet recruiting
- Glioblastoma Multiforme of Brain
- CHM-1101 CAR-T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 19, 2022
B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)
Recruiting
- B Cell Malignancies
- Universal CD19-specific CAR gene-engineered T cells
-
Beijing, Beijing, China
- +2 more
Aug 8, 2023
B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/70 T cells)
Recruiting
- B Cell Malignancies
- bi-4SCAR CD19/70 T cells
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Jun 28, 2022
B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/22 T cells)
Recruiting
- B Cell Malignancies
- bi-4SCAR CD19/22 T cells
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Jun 21, 2022
CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Suzhou (ThisCART19A with Dose Level 1, ThisCART19A with Dose Level
Recruiting
- CAR
- +2 more
- ThisCART19A with Dose Level 1
- ThisCART19A with Dose Level 2
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jan 18, 2023
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders Trial in Chapel Hill (iC9-CAR19 cells,
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- iC9-CAR19 cells
- +3 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 21, 2022
Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)
Not yet recruiting
- Lymphoma, B-Cell
- CD19 and CD22 targeted CAR-T cells
-
Langfang, Hebei, ChinaHebei Yanda Ludaopei Hospital
Dec 6, 2022
B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/79b T cells)
Recruiting
- B Cell Malignancies
- bi-4SCAR CD19/79b T cells
-
Shenzhen, Guangdong, ChinaShenzhen Geno-immune Medical Institute
Jun 28, 2022
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Duarte
Not yet recruiting
- Castration-Resistant Prostate Carcinoma
- +2 more
- Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
- +7 more
-
Duarte, CaliforniaCity of Hope Medical Center
Apr 5, 2023
CNS Lymphoma Trial in Duarte (procedure, biological, drug)
Recruiting
- Central Nervous System Lymphoma
- Aspiration
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Dec 8, 2022
Refractory or Relapsed B Cell Lymphoma Trial in Chongqing (ThisCART19A, Fludarabine, Cyclophosphamide)
Not yet recruiting
- Refractory or Relapsed B Cell Lymphoma
- ThisCART19A
- +3 more
-
Chongqing, Chongqing, ChinaChongqing University Cancer Hospital
Mar 8, 2023
Lymphoma, Lymphoma, B-Cell, Immune System Diseases Trial in Chapel Hill (iC9-CAR19 T cells, Bendamustine, Fludarabine)
Recruiting
- Lymphoma
- +4 more
- iC9-CAR19 T cells
- +4 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2022
Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma Trial in Duarte (Chlorotoxin
Recruiting
- Recurrent Glioblastoma
- +3 more
- Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)
- Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 25, 2022
Relapase and Refractory B-cell Non-Hodgkin's Lymphoma, Decitabine-primed Tandem CD19/CD20 CAR T Cells Trial in Beijing
Recruiting
- Relapase and Refractory B-cell Non-Hodgkin's Lymphoma
- Decitabine-primed Tandem CD19/CD20 CAR T Cells
- Decitabine-primed Tandem CAR19/20 engineered T cells
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinese PLA General Hospital
Mar 24, 2022
B-cell Non Hodgkin Lymphoma Trial in Augsburg, Cologne, Hamburg (MB-CART2019.1 Dose level 1, MB-CART2019.1 Dose level 2)
Active, not recruiting
- B-cell Non Hodgkin Lymphoma
- MB-CART2019.1 Dose level 1
- MB-CART2019.1 Dose level 2
-
Augsburg, Bavaria, Germany
- +2 more
Jun 13, 2022
Large B-cell Lymphoma Trial in Philadelphia (mosunetuzumab, glofitamab, obinutuzumab)
Recruiting
- Large B-cell Lymphoma
- mosunetuzumab
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jul 21, 2022
Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders Trial in Chapel Hill (iC9-CAR19 cells,
No longer available
- Acute Lymphoblastic Leukemia
- +2 more
- iC9-CAR19 cells
- +3 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 2, 2021
B-cell Leukemia, B-Cell Lymphoma Trial in Uppsala (CAR T cells)
Completed
- B-cell Leukemia
- B-Cell Lymphoma
- CAR T cells
-
Uppsala, SwedenUppsala University Hospital, Dept of Oncology
Oct 14, 2021
B-Cell Acute Lymphoblastic Leukemia, Adult Trial in Hangzhou (CAR-T cells targeting CD19 and CD22)
Recruiting
- B-Cell Acute Lymphoblastic Leukemia, Adult
- CAR-T cells targeting CD19 and CD22
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Mar 5, 2021
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 Trial in Duarte
Recruiting
- Castration-Resistant Prostate Carcinoma
- +4 more
- Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 17, 2022